Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.

The ratio change is intended to enable Akari to maintain compliance with the Nasdaq minimum bid price requirement for continued listing. On the effective date, each ADS holder will be required to exchange every forty ADSs for one new ADS. Deutsche Bank, the depositary bank, will arrange for the exchange of the current ADSs for the new ADSs. There is no change to Akari's underlying ordinary shares, and Akari's ADSs will continue to trade on the NASDAQ Capital Market under the symbol AKTX.

No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by Deutsche Bank.

Akari can give no assurances of the performance of the ADS price following the ratio change.